New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Curr Pharm Biotechnol 2006;7:371-9.Kimura S,Ashihara E,Maekawa T. Newtyrosine kinase inhibitors in the treatment of chronic myeloid leukemia[J].Current Pharmaceutical Biotechnology,2006,(05):371-379....
Shakiba Y, Arshadi D. Inhibition of Corneal Neovascularization with new Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptors: Sunitinib malate and Sorafenib. Irn J Med Hypotheses Ideas 2007; 1:1.Y. SHAKIBA ET AL: " Inhibition of Corneal Neovascularization with new Tyrosine...
New BCR-ABL tyrosine kinase inhibitors for imatinib-resistant leukemiasdoi:10.1016/S1548-5315(11)70013-4Dasatinib and nilotinibprovide a novel and effective approach to treating imatinib-resistant CML and Philadelphia chromosome-positive ALL.Jame
New and established tyrosine kinase inhibitors for chronic myeloid leukemia. Chronic myeloid leukemia (CML) is an uncommon malignancy, the treatment and prognosis of which have dramatically shifted over the last decade. Characterize... CD Thienelt,K Green,DW Bowles - 《Drugs of Today》 被引量: ...
traditional treatments in chronic myeloid leukemia(CML),non-small cell lung cancer(NSCLC) and renal cell carcinoma(RCC);some of them already have become the first-line treatment of tumors.In the present paper,the current status of the new drug RD of small-molecule tyrosine kinase inhibitors was...
more visits to the doctor over a longer period; becoming a cancer survivor has psychological and physical sequelae that are only beginning to be appreciated; but the focus of this editorial is the toxicities of the targeted therapies, particularly the small molecule tyrosine kinase inhibitors (TKIs...
Additionally, evaluating the cardiotoxicity of chemotherapeutic agents, including some anthracyclines, tyrosine kinase inhibitors (TKIs), and monoclonal antibodies can significantly assist healthcare providers in choosing the most appropriate medications for their patients, thus potentially reducing adverse effects...
In addition to epigenetic targeting, TCR-signaling targeting with tyrosine kinase inhibitors is under evaluation. Promising efficacy was reported for Duvelisib, a PI3K inhibitor, in relapsed/refractory patients99, and a phase I clinical trial was reported in 2020 using Dasatinib, a multi-kinase inhibi...
In the case of RA, kinases play a central role in the aberrant immune system activation and hence have been targeted using small molecule inhibitors. Mitogen-activated phosphokinase p38 (MAPK), spleen tyrosine kinase (Syk), and Janus kinases (JAKs) have been studied extensively in clinical ...
In the case of RA, kinases play a central role in the aberrant immune system activation and hence have been targeted using small molecule inhibitors. Mitogen-activated phosphokinase p38 (MAPK), spleen tyrosine kinase (Syk), and Janus kinases (JAKs) have been studied extensively in clinical ...